Skip to main content
Toggle navigation
Login
Search
Home
iwCLL X / Twitter
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Favorite
Tweet
Mary C. Collins, BS
Department of Medical Oncology, Dana-Farber Cancer Institute
N/A
Poster(s):
1206 - First-in-human open-label study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor, in patients with relapsed/refractory chronic lymphocytic leukemia and other hematologic malignancies
